Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Cinqair reslizumab Asthma, eosinophilic Reimburse with clinical criteria and/or conditions Complete
Cinqair Reslizumab Asthma, eosinophilic Reimburse with clinical criteria and/or conditions Complete
Cipralex Escitalopram oxalate Depression, Major Depressive Disorder (MDD) Withdrawn
Cipralex Escitalopram oxalate Depression, Major Depressive Disorder (MDD) Do not list Complete
Ciprodex Ciprofloxacin hydrochloride and dexamethasone otic suspension Otitis media with otorrhea & otitis externa, acute Do not list Complete
Ciprodex Ciprofloxacin hydrochloride & dexamethasone otic suspension Otitis media with otorrhea & otitis externa, acute List with clinical criteria and/or conditions Complete
Clolar clofarabine Acute lymphoblastic leukemia CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Columvi glofitamab Relapsed or refractory diffuse large B-cell lymphoma Reimburse with clinical criteria and/or conditions Complete
Combigan Ophthalmic Solution Brimonidine tartrate/timolol maleate Glaucoma List with clinical criteria and/or conditions Complete
COMPLERA Emtricitabine/ rilpivirine/ tenofovir disoproxil fumarate HIV infection List Complete
Constella Linaclotide Irritable bowel syndrome with constipation Do not list Complete
Contrave naltrexone hydrochloride and bupropion hydrochloride Chronic weight management in adults Do not reimburse Complete
Copaxone Glatiramer acetate Clinically Isolated Syndrome (CIS), suggestive of Multiple Sclerosis Do not list Complete
Cortiment Budesonide Ulcerative Colitis Do not reimburse Complete
Corzyna ranolazine Stable angina pectoris, adults Do not reimburse Complete
Cosentyx Secukinumab Plaque psoriasis List with criteria/condition Complete
Cosentyx Secukinumab ankylosing spondylitis Reimburse with clinical criteria and/or conditions Complete
Cosentyx Secukinumab Arthritis, psoriatic Reimburse with clinical criteria and/or conditions Complete
Cosentyx secukinumab Hidradenitis suppurativa Active
Cotellic Cobimetinib Metastatic melanoma Reimburse with clinical criteria and/or conditions Complete
Cresemba isavuconazole Treatment of invasive aspergillosis and mucormycosis Reimburse with clinical criteria and/or conditions Complete
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Reimburse with clinical criteria and/or conditions Complete
Crysvita burosumab Treatment of X-Linked Hypophosphatemia Active
Cubicin Daptomycin Skin and skin structure infections & bacteremia Do not list Complete
Cuvposa glycopyrrolate chronic severe drooling, neurologic (pediatric) Do not reimburse Complete